CTBO (Cantabio Pharmaceuticals) ROC %: -62.97% (As of Dec. 2018)


What is Cantabio Pharmaceuticals ROC %?

Cantabio Pharmaceuticals CTBO ROC % is -62.97% as of Dec. 2018.

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Cantabio Pharmaceuticals's annualized return on capital (ROC %) for the quarter that ended in Dec. 2018 was -62.97%.

As of today (2026-06-26), Cantabio Pharmaceuticals's WACC % is 0.00%. Cantabio Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Cantabio Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Cantabio Pharmaceuticals  (OTCPK:CTBO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cantabio Pharmaceuticals's WACC % is 0.00%. Cantabio Pharmaceuticals's ROC % is 0.00% (calculated using TTM income statement data). Cantabio Pharmaceuticals earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Cantabio Pharmaceuticals ROC % Related Terms

Cantabio Pharmaceuticals ROC % Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals ROC % Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
ROC %
Get a 7-Day Free Trial 0.00 0.00 0.00 -289.70 -171.41

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.07 -225.14 -65.65 -56.54 -62.97

Cantabio Pharmaceuticals ROC % Calculation

Cantabio Pharmaceuticals's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2018 is calculated as:

ROC % (A: Mar. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2017 ) + Invested Capital (A: Mar. 2018 ))/ count )
=-1.349 * ( 1 - 0% )/( (0.369 + 1.205)/ 2 )
=-1.349/0.787
=-171.41 %

where

Invested Capital(A: Mar. 2017 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.034 - 0.518 - ( 0.032 - max(0, 0.887 - 0.034+0.032))
=0.369

Invested Capital(A: Mar. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.109 - 0.778 - ( 0.109 - max(0, 1.983 - 0.109+0.109))
=1.205

Cantabio Pharmaceuticals's annualized Return on Capital (ROC %) for the quarter that ended in Dec. 2018 is calculated as:

ROC % (Q: Dec. 2018 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2018 ) + Invested Capital (Q: Dec. 2018 ))/ count )
=-0.96 * ( 1 - 0% )/( (1.64 + 1.409)/ 2 )
=-0.96/1.5245
=-62.97 %

where

Invested Capital(Q: Sep. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.022 - 0.804 - ( 0.022 - max(0, 2.444 - 0.022+0.022))
=1.64

Invested Capital(Q: Dec. 2018 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0.326 - 0.806 - ( 0.283 - max(0, 2.215 - 0.326+0.283))
=1.409

Note: The Operating Income data used here is four times the quarterly (Dec. 2018) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROC % →
What does a ROC % of -62.97% mean?
Cantabio Pharmaceuticals (CTBO) has a ROC % of -62.97% as of Dec. 2018. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' ROC % too high?
Cantabio Pharmaceuticals' current ROC % is -62.97%.
How does Cantabio Pharmaceuticals' ROC % compare to TNTY and ETNI?
Cantabio Pharmaceuticals' ROC % of -62.97% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC % for a Biotechnology company?
A good ROC % depends on the Biotechnology industry context. However, ROC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC % mean?
A high ROC % can signal that a stock is expensive relative to its fundamentals. Return on capital is the ratio of current-period net income to average two-period capital. View historical data on Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current ROC % is -62.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current ROC % of -62.97%. The current ROC % is -62.97%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC % calculated?
ROC % is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current ROC % is -62.97% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.